Four-year-old boy From Kolkata is Treated for Autism Through Cord Blood Stem Cells

Wednesday, April 4, 2018 Genetics & Stem Cells News
Email Print This Page Comment bookmark
Font : A-A+

CHENNAI, April 4, 2018 /PRNewswire/ --


was done in a clinical trial conducted at Duke University using umbilical cord stem cells preserved at LifeCell

Four-year-old boy, Apartim Dey Singha resident of Kolkata, has been treated through stem cell transplant

for Attention Deficit Hyperactive Disorder - autism at the Duke University clinical trial for treatment of autism through autologous (own stem cells) cord blood stem cell transplants.

     (Logo: )

Autism is a developmental disorder that impairs the social ability to interact and manifests itself through speech disability and other social behavioural issues. Autistic kids have difficulty in expressing themselves and their inability can be clearly noticed by the parent or the caretaker. It is the third most common developmental disorder in which, according to few experts, one in 166 children are affected in India. Structural damage to the brain, toxins, pollutants and environmental related, genetic metabolic, etc., are few of the most common causes associated with autism.

Early diagnosis of autism, coupled with swift and effective intervention, is paramount to achieving the best possible prognosis for the child. In recent times, stem cell transplant is emerging as one of the newer treatment options for autism. It has the potential to repair the damaged neural tissue at molecular, structural and functional level.

Apurba Dey Singha, Apartim's father said, "Initially when we got to know that our son was suffering from autism we didn't know how to take it but we were determined to get him treated and help him overcome the disorder. Our first step was to speak and consult with various healthcare experts. We browsed through the Internet and learnt about autologous stem cell transplant (using own stem cells) for autism. We were happy that we made a wise decision of preserving our baby's umbilical cord stem cells at birth in 2014 with LifeCell, which were used to treat my son for autism. Today, we are seeing great progress in terms of development milestones in my son."

Mayur Abhaya, CEO, MD, LifeCell said, " It's heart-warming to see clinical improvement and development milestones in Apartim Dey Singha. Recently, scientists at Duke University have published results of their study which indicates improvement in autistic children post infusion of autologous umbilical cord stem cells and this improvement has further validated the high-quality preservation standards of stem cells at LifeCell. There are many ongoing clinical trials across the world and this certainly gives hope to parents who have preserved their baby's stem cells at birth."

Results of the Duke University Phase 1 Clinical Trial proves autologous cord blood infusions are safe and feasible in young children with ASD. Significant improvements in children were observed on parent-report measures of social communication skills, expressive vocabulary, eye-tracking measures to social stimuli and behavioral parameters during the first six months after infusion. These data will serve as the basis for future studies to determine the efficacy of umbilical cord blood infusions in children with ASD.

About LifeCell 

LifeCell, established in 2004, is India's leading provider of preventive healthcare services for family wellness, such as stem cell banking and diagnostic testing, with facilities at Chennai and Gurgaon, and a network spanning over 200 cities in India and abroad. Over 3,00,000 lakh parents already having trusted LifeCell for umbilical cord stem cell preservation services.

BabyCord Share, a community-based approach towards stem cell access, is a global first initiative that aims to provide families in India better future access to stem cells than even currently possible in advanced countries such as the U.S. LifeCell's processing, storage and testing facilities are the most accredited having received recognitions from domestic and global bodies such as the AABB (formerly American Association of Blood Banks), College of American Pathologists, National Accreditation Board for Laboratories, World Health Organization, amongst many others, and is also U.S. FDA registered.

Visit us at:

Media Contact : Krutika Rajkumar +91-9884493607 Senior Manager, Corporate Communications LifeCell

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z


News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store